Skip to main
PFE

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 8%
Hold 42%
Sell 17%
Strong Sell 0%

Bulls say

Pfizer is a well-established pharmaceutical company with a strong presence in global markets, particularly in the emerging markets. Pfizer has a diverse portfolio of products, with a focus on prescription drugs and vaccines. Despite its recent patent challenges and emerging market controversies, Pfizer's acquisition of Metsera provides promising new growth drivers and differentiation in the market, potentially improving persistence rates and expanding the addressable patient population and market opportunity in obesity. Overall, Pfizer's portfolio, global presence, and potential for continued growth make it a promising stock in the pharmaceutical industry.

Bears say

Pfizer is facing multiple challenges as a major player in the pharmaceutical market, including increasing competition, a shift towards prescription drugs and vaccines being the main source of revenue, and the negative impact of COVID-19. With a large portion of its sales coming from emerging markets and a major patent expiry in 2025, Pfizer's financial outlook is uncertain and may face pressure in the coming years. Despite recent acquisition of Metsera, Pfizer's overall outlook remains negative due to slow growth potential, potential legal challenges, and limited capacity for business development.

Pfizer (PFE) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 8% recommend Buy, 42% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Buy based on their latest research and market trends.

According to 12 analysts, Pfizer (PFE) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.